Cellectar Biosciences, Inc.
Every calculator, already run for CLRB
Open the full toolkit →You have the numbers on CLRB. Get the argument.
A written report on which of these readings actually decide the outcome for Cellectar Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering CLRBAnalyst Price Target Disagreement for Cellectar Biosciences, Inc.
Wall Street's bull case implies +549% from the current price; the bear case implies +333%. A 216% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CLRB
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and ne…
CLRB — frequently asked
Is CLRB a buy right now?
Wall Street's consensus rating on Cellectar Biosciences, Inc. is none across 4 analysts, with a mean price target of $11.50 (+398% vs. the current $2.31). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CLRB's next earnings date?
Cellectar Biosciences, Inc. is next scheduled to report earnings around Nov 12, 2026. A full CLRB research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Cellectar Biosciences, Inc.?
Analysts covering Cellectar Biosciences, Inc. (CLRB) range from a bear-case target of $10.00 to a bull-case high of $15.00, with a mean consensus target of $11.50 across 4 analysts. The spread of $5.00 (216% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Cellectar Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Cellectar Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CLRB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Cellectar Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.